ATE154354T1 - Azabicyclische verbindungen, diese enthaltende pharmazeutische zubereitungen und ihre therapeutische verwendung - Google Patents

Azabicyclische verbindungen, diese enthaltende pharmazeutische zubereitungen und ihre therapeutische verwendung

Info

Publication number: ATE154354T1
Authority: AT; Austria
Prior art keywords: trifluoromethyl; independently represent; pharmaceutical preparations; therapeutic use; preparations containing
Prior art date: 1991-02-11

Application number

AT92200303T

Other languages

English (en)

Inventor

Raymond Baker

Christopher Swain

Eileen M Seward

Original Assignee

Merck Sharp & Dohme

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-02-11

Filing date

1992-02-04

Publication date

1997-06-15

1991-02-11 Priority claimed from GB919102809A external-priority patent/GB9102809D0/en

1991-04-09 Priority claimed from GB919107403A external-priority patent/GB9107403D0/en

1991-06-27 Priority claimed from GB919113892A external-priority patent/GB9113892D0/en

1991-07-05 Priority claimed from GB919114553A external-priority patent/GB9114553D0/en

1992-02-04 Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme

1997-06-15 Application granted granted Critical

1997-06-15 Publication of ATE154354T1 publication Critical patent/ATE154354T1/de

Links

150000001875 compounds Chemical class 0.000 title abstract 2
239000000825 pharmaceutical preparation Substances 0.000 title 1
230000001225 therapeutic effect Effects 0.000 title 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 3
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
125000001475 halogen functional group Chemical group 0.000 abstract 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
101100054666 Streptomyces halstedii sch3 gene Proteins 0.000 abstract 1
102000003141 Tachykinin Human genes 0.000 abstract 1
241000534944 Thia Species 0.000 abstract 1
239000005557 antagonist Substances 0.000 abstract 1
125000004093 cyano group Chemical group *C#N 0.000 abstract 1
125000004122 cyclic group Chemical group 0.000 abstract 1
125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
229940002612 prodrug Drugs 0.000 abstract 1
239000000651 prodrug Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
108060008037 tachykinin Proteins 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1
125000001544 thienyl group Chemical group 0.000 abstract 1
125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)
Hospice & Palliative Care (AREA)
Rheumatology (AREA)
Anesthesiology (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

AT92200303T 1991-02-11 1992-02-04 Azabicyclische verbindungen, diese enthaltende pharmazeutische zubereitungen und ihre therapeutische verwendung ATE154354T1 (de)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GB919102809A GB9102809D0 (en)	1991-02-11	1991-02-11	Therapeutic agents
GB919107403A GB9107403D0 (en)	1991-04-09	1991-04-09	Therapeutic agents
GB919113892A GB9113892D0 (en)	1991-06-27	1991-06-27	Therapeutic agents
GB919114553A GB9114553D0 (en)	1991-07-05	1991-07-05	Therapeutic agents

Publications (1)

Publication Number	Publication Date
ATE154354T1 true ATE154354T1 (de)	1997-06-15

Family

ID=27450624

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT92200303T ATE154354T1 (de)	1991-02-11	1992-02-04	Azabicyclische verbindungen, diese enthaltende pharmazeutische zubereitungen und ihre therapeutische verwendung

Country Status (7)

Country	Link
US (1)	US5242930A (de)
EP (1)	EP0499313B1 (de)
JP (1)	JP2500279B2 (de)
AT (1)	ATE154354T1 (de)
CA (1)	CA2060949A1 (de)
DE (1)	DE69220258T2 (de)
IE (1)	IE920435A1 (de)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2149767T5 (es)	1991-09-20	2005-06-16	Glaxo Group Limited	Nuevo uso medico para antagonistas de taquiquininas.
AU675786B2 (en) *	1992-04-15	1997-02-20	Merck Sharp & Dohme Limited	Azacyclic compounds
US6048859A (en)	1992-06-29	2000-04-11	Merck & Co., Inc.	Morpholine and thiomorpholine tachykinin receptor antagonists
US5637699A (en) *	1992-06-29	1997-06-10	Merck & Co., Inc.	Process for preparing morpholine tachykinin receptor antagonists
US5719147A (en) *	1992-06-29	1998-02-17	Merck & Co., Inc.	Morpholine and thiomorpholine tachykinin receptor antagonists
JP2683783B2 (ja) *	1992-07-10	1997-12-03	雪印乳業株式会社	シェーグレン症候群治療剤
GB2268931A (en) *	1992-07-22	1994-01-26	Merck Sharp & Dohme	Azabicyclic tachykinin-receptor antagonists
ATE173725T1 (de) *	1992-07-28	1998-12-15	Merck Sharp & Dohme	Azazyklische verbindungen
GB2269170A (en) *	1992-07-29	1994-02-02	Merck Sharp & Dohme	Azatricyclic tachykinin antagonists
US5387595A (en) *	1992-08-26	1995-02-07	Merck & Co., Inc.	Alicyclic compounds as tachykinin receptor antagonists
GB9220286D0 (en) *	1992-09-25	1992-11-11	Merck Sharp & Dohme	Therapeutic agents
US5837711A (en) *	1992-10-28	1998-11-17	Pfizer Inc.	Substituted quinuclidines as substance P antagonists
ES2147759T3 (es) *	1992-12-10	2000-10-01	Pfizer	Heterociclos no aromaticos sustituidos con aminometileno y uso como antagonistas de la sustancia p.
US5344830A (en) *	1992-12-10	1994-09-06	Merck & Co., Inc.	N,N-diacylpiperazine tachykinin antagonists
US5830854A (en) *	1992-12-14	1998-11-03	Merck Sharp & Dohme, Limited	Method of treating cystic fibrosis using a tachykinin receptor antagonist
GB9226581D0 (en) *	1992-12-21	1993-02-17	Merck Sharp & Dohme	Therapeutic agents
GB9300051D0 (en) *	1993-01-04	1993-03-03	Merck Sharp & Dohme	Therapeutic agents
FR2700472B1 (fr)	1993-01-19	1995-02-17	Rhone Poulenc Rorer Sa	Association synergisante ayant un effet antagoniste des récepteurs NK1 et NK2.
WO1994019323A1 (en) *	1993-02-18	1994-09-01	Merck Sharp & Dohme Limited	Azacyclic compounds, compositions containing them and their use as tachykinin antagonists
US5817679A (en) *	1993-04-01	1998-10-06	University Of Virginia	7-Azabicyclo 2.2.1!-heptane and -heptene derivatives as cholinergic receptor ligands
US6060473A (en) *	1993-04-01	2000-05-09	Ucb S.A. - Dtb	7-azabicyclo[2.2.1]-heptane and -heptene derivatives as cholinergic receptor ligands
CA2167198C (en) *	1993-07-15	1999-03-16	Kunio Satake	Benzylaminoquinuclidines
AU701227B2 (en) *	1993-09-10	1999-01-21	Cytomed, Inc	Epibatidine and derivatives thereof as cholinergic receptor agonists and antagonists
US5610165A (en) *	1994-02-17	1997-03-11	Merck & Co., Inc.	N-acylpiperidine tachykinin antagonists
IL112778A0 (en) *	1994-03-04	1995-05-26	Merck & Co Inc	Substituted heterocycles, their preparation and pharmaceutical compositions containing them
US6117889A (en) *	1994-04-01	2000-09-12	University Of Virginia	7-Azabicyclo-[2.2.1]-heptane and -heptene derivatives as analgesics and anti-inflammatory agents
FR2725900B1 (fr) *	1994-10-21	1997-07-18	Sanofi Sa	Utilisation d'antagonistes des recepteurs nk1 pour la preparation de medicaments a action cardioregulatrice
FR2728169A1 (fr)	1994-12-19	1996-06-21	Oreal	Utilisation d'un antagoniste de substance p pour le traitement des prurits et des dysesthesies oculaires ou palpebrales
FR2728165A1 (fr)	1994-12-19	1996-06-21	Oreal	Utilisation d'un antagoniste de substance p pour le traitement des rougeurs cutanees d'origine neurogene
FR2728166A1 (fr)	1994-12-19	1996-06-21	Oreal	Composition topique contenant un antagoniste de substance p
TW458774B (en)	1995-10-20	2001-10-11	Pfizer	Antiemetic pharmaceutical compositions
FR2741262B1 (fr)	1995-11-20	1999-03-05	Oreal	Utilisation d'un antagoniste de tnf-alpha pour le traitement des rougeurs cutanees d'origine neurogene
EP0912174B1 (de) *	1996-07-17	2004-04-28	MERCK & CO., INC.	Änderung des zirkadischen rhythmus mit nicht-peptidischen neurokinin-1 rezeptor antagonisten
MX9706944A (es) *	1996-09-12	1998-08-30	Pfizer	Quinuclidinas sustituidas con tetrazolilo como antagonistas de la sustancia p.
GB9716463D0 (en) *	1997-08-04	1997-10-08	Merck Sharp & Dohme	Therapeutic agents
DK1246806T3 (da)	1999-11-03	2008-06-16	Amr Technology Inc	Aryl- og heteroarylsubstituerede tetrahydroisoquinoliner og anvendelse deraf til blokering af genoptagelse af norepinefrin, dopsmin og serotonin
US7163949B1 (en)	1999-11-03	2007-01-16	Amr Technology, Inc.	4-phenyl substituted tetrahydroisoquinolines and use thereof
MXPA03000275A (es)	2000-07-11	2004-12-13	Albany Molecular Res Inc	Nuevas tetrahidroisoquinolinas substituidas con 4-fenilo y su uso terapeutico.
GB0108982D0 (en)	2001-04-10	2001-05-30	Merck Sharp & Dohme	Therapeutic agents
US6709651B2 (en)	2001-07-03	2004-03-23	B.M.R.A. Corporation B.V.	Treatment of substance P-related disorders
UA91341C2 (ru)	2004-07-15	2010-07-26	Амр Текнолоджи, Інк.	Арил- и гетероарилзамещенные тетрагидроизохинолины и их применение для блокирования обратного захвата норэпинефрина, допамина и серотонина
EP1855678A2 (de) *	2005-01-07	2007-11-21	Merck & Co., Inc.	Verwendung von 3-substituierten 2-(diphenylmethy)-1-azabicyclo-2.2.2-oktanen zur behandlung von durch mrg-x1-rezeptoren hervorgerufenen krankheiten
ATE550019T1 (de)	2005-05-17	2012-04-15	Merck Sharp & Dohme	Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
US7956050B2 (en)	2005-07-15	2011-06-07	Albany Molecular Research, Inc.	Aryl- and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
KR20080048502A (ko)	2005-09-29	2008-06-02	머크 앤드 캄파니 인코포레이티드	멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체
GB0603041D0 (en)	2006-02-15	2006-03-29	Angeletti P Ist Richerche Bio	Therapeutic compounds
AU2007300627B2 (en)	2006-09-22	2012-02-16	Merck Sharp & Dohme Corp.	Method of treatment using fatty acid synthesis inhibitors
JP5172124B2 (ja) *	2006-09-29	2013-03-27	関東化学株式会社	２位に置換基を有する光学活性キヌクリジノール類の製造方法
JP5232374B2 (ja) *	2006-09-29	2013-07-10	関東化学株式会社	２位に置換基を有する光学活性キヌクリジノール類の製造方法
US20110218176A1 (en)	2006-11-01	2011-09-08	Barbara Brooke Jennings-Spring	Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
BRPI0806245B1 (pt)	2007-01-10	2022-01-25	Msd Italia S.R.L.	Compostos de fórmula i e seus usos
US8093268B2 (en)	2007-01-24	2012-01-10	Glaxo Group Limited	Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-)
AU2008233662B2 (en)	2007-04-02	2012-08-23	Msd K.K.	Indoledione derivative
WO2009002495A1 (en)	2007-06-27	2008-12-31	Merck & Co., Inc.	4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US9156812B2 (en)	2008-06-04	2015-10-13	Bristol-Myers Squibb Company	Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
AR071997A1 (es)	2008-06-04	2010-07-28	Bristol Myers Squibb Co	Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
UA105182C2 (ru)	2008-07-03	2014-04-25	Ньюрексон, Інк.	Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
MX2011004551A (es)	2008-10-30	2011-05-25	Merck Sharp & Dohme	Antagonistas del receptor de orexina de isonicotinamida.
EP2413932A4 (de)	2009-04-01	2012-09-19	Merck Sharp & Dohme	Hemmer der akt-aktivität
ES2446971T3 (es)	2009-05-12	2014-03-11	Albany Molecular Research, Inc.	Tetrahidroisoquinolinas sustituidas con arilo, heteroarilo, y heterociclo y su uso
CN102595902B (zh)	2009-05-12	2015-04-29	阿尔巴尼分子研究公司	7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉及其用途
JP5739415B2 (ja)	2009-05-12	2015-06-24	ブリストル−マイヤーズスクウィブカンパニー	（Ｓ）−７−（［１，２，４］トリアゾロ［１，５−ａ］ピリジン−６−イル）−４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロイソキノリンの結晶形態およびその使用
CA2777043C (en)	2009-10-14	2015-12-15	Schering Corporation	Substituted piperidines that increase p53 activity and the uses thereof
EP2584903B1 (de)	2010-06-24	2018-10-24	Merck Sharp & Dohme Corp.	Neue heterozyklische verbindungen als erk-hemmer
CN103068980B (zh)	2010-08-02	2017-04-05	瑟纳治疗公司	使用短干扰核酸（siNA）的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1（CTNNB1）基因表达的抑制
RU2745848C2 (ru)	2010-08-17	2021-04-01	Сирна Терапьютикс, Инк.	ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
US8883801B2 (en)	2010-08-23	2014-11-11	Merck Sharp & Dohme Corp.	Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
EP2613782B1 (de)	2010-09-01	2016-11-02	Merck Sharp & Dohme Corp.	Indazolderivate als erk-hemmer
US9242981B2 (en)	2010-09-16	2016-01-26	Merck Sharp & Dohme Corp.	Fused pyrazole derivatives as novel ERK inhibitors
WO2012058210A1 (en)	2010-10-29	2012-05-03	Merck Sharp & Dohme Corp.	RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
WO2012087772A1 (en)	2010-12-21	2012-06-28	Schering Corporation	Indazole derivatives useful as erk inhibitors
WO2012143879A1 (en)	2011-04-21	2012-10-26	Piramal Healthcare Limited	A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
AR088352A1 (es)	2011-10-19	2014-05-28	Merck Sharp & Dohme	Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
EP2770987B1 (de)	2011-10-27	2018-04-04	Merck Sharp & Dohme Corp.	Neue verbindungen als erk-hemmer
EP3919620A1 (de)	2012-05-02	2021-12-08	Sirna Therapeutics, Inc.	Zusammensetzungen mit kurzer interferierender nukleinsäure (sina)
CA2882950A1 (en)	2012-09-28	2014-04-03	Merck Sharp & Dohme Corp.	Novel compounds that are erk inhibitors
SMT201700595T1 (it)	2012-11-28	2018-03-08	Merck Sharp & Dohme	Composizioni e metodi per trattare il cancro
WO2014100065A1 (en)	2012-12-20	2014-06-26	Merck Sharp & Dohme Corp.	Substituted imidazopyridines as hdm2 inhibitors
WO2014120748A1 (en)	2013-01-30	2014-08-07	Merck Sharp & Dohme Corp.	2,6,7,8 substituted purines as hdm2 inhibitors
WO2015034925A1 (en)	2013-09-03	2015-03-12	Moderna Therapeutics, Inc.	Circular polynucleotides
US10975084B2 (en)	2016-10-12	2021-04-13	Merck Sharp & Dohme Corp.	KDM5 inhibitors
EP3706742B1 (de)	2017-11-08	2023-03-15	Merck Sharp & Dohme LLC	Prmt5-inhibitoren
WO2019094312A1 (en)	2017-11-08	2019-05-16	Merck Sharp & Dohme Corp.	Prmt5 inhibitors
WO2020033282A1 (en)	2018-08-07	2020-02-13	Merck Sharp & Dohme Corp.	Prmt5 inhibitors
CA3108388A1 (en)	2018-08-07	2020-02-13	Merck Sharp & Dohme Corp.	Prmt5 inhibitors
WO2020033285A1 (en)	2018-08-07	2020-02-13	Merck Sharp & Dohme Corp.	Prmt5 inhibitors
EP3833667B1 (de)	2018-08-07	2024-03-13	Merck Sharp & Dohme LLC	Prmt5-inhibitoren
US11098029B2 (en)	2019-02-13	2021-08-24	Merck Sharp & Dohme Corp.	5-alkyl pyrrolidine orexin receptor agonists
WO2020167701A1 (en)	2019-02-13	2020-08-20	Merck Sharp & Dohme Corp.	Pyrrolidine orexin receptor agonists
EP4010314B1 (de)	2019-08-08	2024-02-28	Merck Sharp & Dohme LLC	Heteroaryl-pyrrolidin- und piperidinorexinrezeptor-agonisten
ES3022307T3 (en)	2019-12-17	2025-05-28	Merck Sharp & Dohme Llc	Prmt5 inhibitors
EP4076460B1 (de)	2019-12-17	2026-01-21	Merck Sharp & Dohme LLC	1,4-dihydro-2h-spiro[isoquinoline-3,4'-piperidin]-derivate als prmt5 inhibitoren zur behandlung von krebs
US20230365533A1 (en)	2020-08-18	2023-11-16	Merck Sharp & Dohme Llc	Bicycloheptane pyrrolidine orexin receptor agonists

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3506673A (en) *	1968-03-29	1970-04-14	Aldrich Chem Co Inc	2-(4'halo)-benzhydryl-3-quinuclidinols
US3796714A (en) *	1971-07-01	1974-03-12	Hercules Inc	Lactone and sultone adducts of bicyclic tertiary amines
US4013667A (en) *	1976-03-08	1977-03-22	G. D. Searle & Co.	2,2-Diaryl-3-(1-azabicyclo[2.2.2]oct-2-yl)propionamides and intermediates thereto
US4013668A (en) *	1976-03-10	1977-03-22	G. D. Searle & Co.	5-(1,1-diphenyl-3-(5- or 6-hydroxy-2-azabicyclo(2.2.2)oct-2-yl)propyl)-2-alkyl-1,3,4-oxadiazoles and related compounds
US4125531A (en) *	1977-04-18	1978-11-14	G. D. Searle & Co.	2-Substituted-1-azabicyclo[2.2.2]octanes
US4599344A (en) *	1984-10-31	1986-07-08	Schering A.G.	Quinuclidines and quinuclidinium salts as antiarrhythmic agents
FI864606A0 (fi) *	1985-03-27	1986-11-12	Potemkin Gennady Y	Verktyg foer bearbetning av haol.
MX18467A (es) *	1988-11-23	1993-07-01	Pfizer	Agentes terapeuticos de quinuclidinas

1992
- 1992-02-04 US US07/830,822 patent/US5242930A/en not_active Expired - Lifetime
- 1992-02-04 DE DE69220258T patent/DE69220258T2/de not_active Expired - Fee Related
- 1992-02-04 AT AT92200303T patent/ATE154354T1/de not_active IP Right Cessation
- 1992-02-04 EP EP92200303A patent/EP0499313B1/de not_active Expired - Lifetime
- 1992-02-10 CA CA002060949A patent/CA2060949A1/en not_active Abandoned
- 1992-02-10 IE IE043592A patent/IE920435A1/en not_active Application Discontinuation
- 1992-02-12 JP JP4025068A patent/JP2500279B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
JP2500279B2 (ja)	1996-05-29
US5242930A (en)	1993-09-07
CA2060949A1 (en)	1992-08-12
EP0499313A1 (de)	1992-08-19
DE69220258T2 (de)	1997-12-18
IE920435A1 (en)	1992-08-12
EP0499313B1 (de)	1997-06-11
JPH0578354A (ja)	1993-03-30
DE69220258D1 (de)	1997-07-17

Legal Events

Date	Code	Title	Description
1997-12-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE69220258D1 (de)	1997-07-17	Azabicyclische Verbindungen, diese enthaltende pharmazeutische Zubereitungen und ihre therapeutische Verwendung
ATE233761T1 (de)	2003-03-15	Neue chinuclidin-derivate und diese enthaltende pharmazeutische präparate
DE69208088D1 (de)	1996-03-14	Aromatische verbindungen, diese enthaltende pharmazeutische zusammensetzungen und ihre therapeutische anwendung
DE69208089D1 (de)	1996-03-14	Aromatische verbindungen diese enthaltende pharmazeutische zusammensetzungen und ihre therapeutische verwendung
DE69529670D1 (de)	2003-03-27	Oxazolidinon derivate und diese enthaltende pharmazeutische zusammensetzungen
PT1235826E (pt)	2004-01-30	Acrilamidas de quinuclidina
DZ863A1 (fr)	2004-09-13	Dérivés de benzoxazol et benzothiazolamine.
ATE106403T1 (de)	1994-06-15	Isoxazol-derivate mit anti-serotonin-aktivität, deren herstellungsverfahren und diese enthaltende zusammensetzungen.
DE69429591D1 (de)	2002-02-14	Therapeutisch wirksame Verbindungen
ATE305473T1 (de)	2005-10-15	Pdgf-rezeptor-kinase hemmende verbindungen, deren herstellung, reinigung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
NO943895D0 (no)	1994-10-14	Galantaminderivater, en fremgangsmåte for fremstilling samt deres anvendelse som medikamenter
SE8404065D0 (sv)	1984-08-10	Novel biologically active compounds
FR2683819B1 (fr)	1994-02-11	Derives de quinoleine, leur procede de preparation et leur application en therapeutique.
ATE161531T1 (de)	1998-01-15	Acridine-1,8-dionderivate als therapeutisches mittel
FI821253L (fi)	1982-10-08	Galenisk produkt
ATE8144T1 (de)	1984-07-15	Indolobenzoxazine, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen.
ATE24509T1 (de)	1987-01-15	Triazoloquinazolone und deren salze, verfahren und zwischenprodukte zu ihrer herstellung, ihre verwendung als arzneimittel und diese enthaltende zusammensetzungen.
FI833453A0 (fi)	1983-09-26	Terapeutiska medel
DE69105786D1 (de)	1995-01-26	Harnstoffderivate, deren Herstellung sowie diese enthaltende pharmazeutische Zusammensetzungen.
NO913023L (no)	1991-08-02	Nye bicykliske aminosubstituerte forbindelser
ATE88176T1 (de)	1993-04-15	2-hydroxy-3-aryloxy-propylaminderivate mit kardiovaskulaerer wirkung.
ATE9584T1 (de)	1984-10-15	Antibakterielle beta-lactam-verbindungen, ihre herstellung und sie enthaltende pharmazeutische zusammensetzungen.
ATE102942T1 (de)	1994-04-15	Antirhinovirale pyridazinamine.
ATE145911T1 (de)	1996-12-15	Inositol-phosphat-analog als kalzium- antagonistische substanz
DE3862426D1 (de)	1991-05-23	2-selenomethyl-1,4-dihydropyridine, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.